---
title: "Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review"
description: "New drug review on Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration, for pharmacy and therapeutics review. Covers Indications, Pharmacokinetics, Drug interactions, Adverse drug events, Dosing and administration, and Effectiveness. 20 evidence topics quoted from 3 sources. Every table value is a verbatim quote from the prescribing information cited beneath it; a fact the label does not carry is quoted below its table, with its own source."
canonical: "https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review"
published: "2026-09-28T12:24:10-04:00"
modified: "2026-10-28T12:03:51-04:00"
---

# Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review

<a id="review-monograph-review-section"></a>

## Review section

<a id="review-monograph-topic-review-section-1"></a>

| Field | Value |
| --- | --- |
| Drug | Lytenava (bevacizumab-vikg) |
| Indication reviewed | Neovascular age-related macular degeneration |
| Therapeutic category | Ophthalmic vascular endothelial growth factor (VEGF) inhibitors (intravitreal anti-VEGF monoclonal antibody) |
| Manufacturer | Outlook Therapeutics |
| Regulatory status | Approved July 24, 2026 |
| Data as of | September 28, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |

<a id="review-monograph-indications"></a>

## 1 Indications

<a id="review-monograph-topic-1-1"></a>

### Table 1. FDA-approved indications

| Indications | Lytenava (bevacizumab-vikg) |
| --- | --- |
| “treatment of patients with neovascular (wet) age-related macular degeneration (nAMD)” | ✓ |

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-1-2"></a>

### Trial in which efficacy was established

> “The efficacy of LYTENAVA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) was demonstrated in a randomized, multi-center, masked, active-controlled study (NORSE TWO – NCT03834753).”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-1-3"></a>

### Age limit of the indication

> “The safety and effectiveness of LYTENAVA in pediatric patients have not been established.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-pharmacokinetics"></a>

## 2 Pharmacokinetics

<a id="review-monograph-topic-2-1"></a>

### Table 2. Pharmacokinetic parameters

| Generic Name(s) | Bioavailability | Protein Binding | Metabolism | Excretion | Half-Life |
| --- | --- | --- | --- | --- | --- |
| Bevacizumab-vikg | Not reported | Not reported | Not reported | Not reported | Not reported |

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-2-2"></a>

### Systemic exposure after intravitreal injection

> “Following intravitreal administration of LYTENAVA, the systemic exposure to bevacizumab-vikg is minimal.”
> “In 14 subjects who received a single 1.25 mg dose of LYTENAVA, the serum bevacizumab-vikg concentration was assessed up to Day 4. The serum bevacizumab-vikg concentrations gradually increased over time, so the highest concentrations observed were approximately at Day 4 (the last collection time) ranging from 33 to 270 ng/mL, which was <1% of the Cmax after intravenous infusion of 2 mg/kg bevacizumab-vikg. However, due to the limited sample collection, Cmax or AUC could not be adequately characterized.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-2-3"></a>

### Immunogenicity

> “In a 52-week study, a total of 14 subjects who received LYTENAVA and were subsequently evaluated for immunogenicity did not show detectable ADA at any timepoint but the ADA assay sensitivity data in the presence of free drug was insufficient. However, due to the minimal systemic exposure to LYTENAVA following intravitreal injection, the risk of immunogenicity is not expected to be clinically significant.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-drug-interactions"></a>

## 3 Drug interactions

<a id="review-monograph-topic-3-1"></a>

### Table 3. Major drug interactions

No evidence found.

<a id="review-monograph-topic-3-2"></a>

### Contents of the prescribing information, which list no drug interactions section

> “6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 8 USE IN SPECIFIC POPULATIONS”
> “Sections or subsections omitted from the full prescribing information are not listed.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-adverse-drug-events"></a>

## 4 Adverse drug events

<a id="review-monograph-topic-4-1"></a>

### Table 4. Adverse drug events reported in 1% or more of patients across five clinical trials

| Adverse Event | Lytenava 1.25 mg (N = 601), % | Ranibizumab 0.5 mg (N = 345), % |
| --- | --- | --- |
| Conjunctival hemorrhage | “4%” | “3%” |
| Eye pain | “2%” | “1%” |
| Vitreous floaters | “2%” | “1%” |

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-4-2"></a>

### Safety population and comparator in Table 4

> “The data described below reflect exposure to LYTENAVA in 601 patients, in five clinical trials”
> “Table 1 shows the most common ocular adverse reactions in LYTENAVA treated patients compared with ranibizumab 0.5 mg.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-4-3"></a>

### Less common ocular adverse reactions

> “Less common ocular adverse reactions reported in the study eye in <1% of patients treated with LYTENAVA were corneal abrasion, dry eye, eye irritation, and intraocular pressure increased.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-4-4"></a>

### Warnings and precautions

> “Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering LYTENAVA.”
> “Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA.”
> “Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-4-5"></a>

### Contraindications

> “LYTENAVA is contraindicated in patients with ocular or periocular infections.”
> “LYTENAVA is contraindicated in patients with active intraocular inflammation.”
> “LYTENAVA is contraindicated in patients with known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-dosing-and-administration"></a>

## 5 Dosing and administration

<a id="review-monograph-topic-5-1"></a>

### Table 5. Usual dosing regimens

| Generic Name | Usual Adult Dose | Usual Pediatric Dose | Availability |
| --- | --- | --- | --- |
| Bevacizumab-vikg | “The recommended dose for LYTENAVA is 1.25 mg (0.05 mL of 25 mg/mL) administered by intravitreal injection once monthly (approximately 28 days).” “LYTENAVA must only be administered by a qualified physician.” | “The safety and effectiveness of LYTENAVA in pediatric patients have not been established.” | “Injection: 1.25 mg (0.05 mL of 25 mg/mL) colorless to light brown, opalescent solution for intravitreal injection in a single-dose vial.” “Each carton (NDC 82491-025-10) contains LYTENAVA 1.25 mg (0.05 mL of 25 mg/mL bevacizumab-vikg solution) in a single-dose glass vial with a BLUE CAP.” |

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

See the current prescribing information for full details.

<a id="review-monograph-topic-5-2"></a>

### Devices, preparation, and single-eye use

> “A 5-micron sterile filter needle (18-gauge x 1½-inch), a 1-mL syringe (with marking to measure 0.05 mL), and a 30-gauge x ½-inch sterile injection needle are needed.”
> “The glass vial is for one-time use in one eye only.”
> “Each single-dose vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter needle, and injection needles should be changed before LYTENAVA is administered to the other eye.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-5-3"></a>

### Injection procedure and post-injection monitoring

> “The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to injection.”
> “Prior to and 30 minutes following the intravitreal injection, patients should be monitored for elevation in intraocular pressure using tonometry.”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-effectiveness"></a>

## 6 Effectiveness

<a id="review-monograph-topic-6-1"></a>

### Table 6. Comparative clinical trials

| Study and Drug Regimen | Study Design and Demographics | Study Size and Duration | End Points | Results |
| --- | --- | --- | --- | --- |
| NORSE TWO (NCT03834753): “randomized to LYTENAVA 1.25 mg (N=113) administered once monthly for 1 year or ranibizumab 0.5 mg (N=115) administered once monthly for 3 months (Days 0, 30, and 60) followed by once every 3 months for 1 year (Days 150 and 240)” | “a randomized, multi-center, masked, active-controlled study” “adult patients with nAMD” “Patient ages ranged from 54 to 98 years, with a median age of 79 years.” | “LYTENAVA 1.25 mg (N=113)” “ranibizumab 0.5 mg (N=115)” “once monthly for 1 year” | Primary: “The primary efficacy endpoint was the proportion of patients who gained ≥ 15 Best Corrected Visual Acuity (BCVA) letters from baseline to Month 11 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.” Secondary: “The pre-specified secondary efficacy endpoint of mean change in BCVA from baseline to Month 11” | Patients gaining ≥15 letters, n/N (%): Lytenava “45/108 (41.7)” Ranibizumab “24/104 (23.1)” Risk difference: “0.1859” 95% CI: “0.0442, 0.3086” “The difference observed between the study drug groups was significant, in favor of LYTENAVA” Mean change in BCVA: “favored LYTENAVA once monthly compared to ranibizumab administered once monthly for 3 months then every 3 months” |
| NORSE EIGHT (NCT06190093): “randomized (1:1) to LYTENAVA 1.25 mg or ranibizumab 0.5 mg, administered every 4 weeks for 3 total doses (Day 0, Week 4, and Week 8)” | “a multicenter, randomized, masked, controlled study” | “400 adult patients with nAMD” “every 4 weeks for 3 total doses (Day 0, Week 4, and Week 8)” | Primary: “The primary efficacy endpoint was the mean change in baseline BCVA as measured by ETDRS score at Week 8 using a non-inferiority (NI) margin of -3.5 letters.” | “At Week 8, the LYTENAVA group had a mean increase in BCVA of 3.3 compared to a mean increase of 4.5 in the ranibizumab group. The LS mean difference and 95% CI was -2.3 (-4.0, -0.5).” “NORSE EIGHT did not meet its pre-specified NI margin of -3.5 letters in mean change from baseline BCVA at Week 8 compared to ranibizumab.” “LYTENAVA showed an increase from baseline in BCVA at Week 12 consistent with NORSE TWO.” |

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

Abbreviations: BCVA=best corrected visual acuity; CI=confidence interval; ETDRS=Early Treatment Diabetic Retinopathy Study; LS=least squares; nAMD=neovascular age-related macular degeneration; NI=non-inferiority

<a id="review-monograph-topic-6-2"></a>

### Age of patients in the Phase 3 trials

> “In the three completed Phase 3 clinical studies, approximately 70% (238/341) of patients treated with LYTENAVA were ≥ 65 years of age and approximately 47 % (160/341) were ≥ 75 years of age. No overall differences in efficacy or safety were seen with increasing age in these studies”

Source: [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="review-monograph-topic-6-3"></a>

### NORSE TWO eligibility, comparator regimen, p-value, and mean change in visual acuity, from the trial publication, which the prescribing information does not state

> “Treatment-naïve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included.”
> “Patients randomized to ONS-5010 received monthly intravitreal doses of 1.25 mg of ONS-5010, bevacizumab-vikg (Outlook Therapeutics) for 12 months. Patients randomized to ranibizumab received 0.50 mg of ranibizumab on days 0, 30, 60, 150, and 240 based on the PIER study dosing regimen.”
> “Respectively, 41.7% and 23.1% of patients gained ≥ 15 letters (3 lines) of visual acuity, with a risk difference of 0.1859 [95% CI = 0.0442, 0.3086]; P = 0.0052. The change in BCVA from baseline to 11 months was found to be 11.2 ± 12.19 and 5.8 ± 14.80 ETDRS letters, respectively.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="review-monograph-topic-6-4"></a>

### NORSE EIGHT Week 12 comparison, from the sponsor, which the prescribing information does not quantify

> “The difference in mean BCVA between ONS-5010 and ranibizumab was -1.009 letters (95% confidence interval, -2.865, 0.848), meeting the noninferiority margin at Month 3 (p=0.0043)”

Source: [Outlook Therapeutics NORSE EIGHT presentation press release (2025)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-presentation-of-efficacy-and-safety-results-from-norse-eight-clinical-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd)

<a id="review-monograph-references"></a>

## 7 References

1. [Lytenava prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)
2. [Outlook Therapeutics NORSE EIGHT presentation press release (2025)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-presentation-of-efficacy-and-safety-results-from-norse-eight-clinical-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd)
3. [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

## Related pages
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: drug evaluation](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
